Molecular biology and genomics — the basis of health and the future of precision medicine
DOI:
https://doi.org/10.52692/1857-0011.2021.2-70.08Keywords:
personalized medicine, precision medicine, genome, chromosome, DNA, genomic medicine, medical nanogenomics, pharmacogenomicsAbstract
Molecular biology and genomics — the basis of health and the future of precision medicine. The contemporary strategy of world medicine is not only personalized medicine based on evidence, on the patient’s profile, but genotype, phenotype, type of metabolism, and environmental factors. We can say that precision medicine will be the medicine of the future. We will also have science — medical nanogenomics. This will be the treatment reform of human medicineReferences
ABPI. The stratification of disease for personalized medicines: Research driven recommendations to strengthen a unified UK strategy through a stakeholder alliance. London: The Association of the British Pharmaceutical Industry; 2014.
Ahrens C.H., Brunner E., Qeli E., Basler K., Aebersold R.Generating and navigating proteome maps using mass spectrometry. Nature Rev Mol Cell Biol. 2010; 11: 789-801.
Aronson S.J., Rehm H.L. Building the foundation for genomics in precision medicine. Nature. 2015; 526: 336-42.
Bensimon A., Heck A.J., Aebersold R. Mass spectrometry-based proteomics and network biology. Annu Rev Biochem. 2012; 81: 379-405.
Blaus A., Madabushi R., Pacanoski M., Rose M., Schuck R.N., Stockbridge N. et al. Personalized cardiovascular medicine today: a Food and Administration/Center for Drug evaluation and research perspective. Circulation. 2015; 132: 1425-32.
Clish C.B. Metabolism: an emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud. 2015; 1: a000588. doi: 10.1101/mcs.a000588.
FDA. Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development. Maryland: U.S. Food and Drug Administration; 2013.
Fernald G.H., Capriotti E., Daneshjou R., Karczewski K.J., Altman R.B. Bioinformatics challenges for personalized medicine. Bioinformatics. 2011; 27: 1741-8.
Gieger C., Geistlinger L., Altmaier E., de Angelis M.H., Kronenberg F., Meitinger T. et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. Plos Gen. 2008; 4: e1000282. doi: 10.1371/journal.pgen.1000282.
Ginsburg G.S., Willard H.F. Genomic and personalized medicine: foundations and applications. Transl Res. 2009; 154: 277-87.
Korf B.R., Rehm H.L. New approaches to molecular diagnosis. J Am Med Assoc. 2013; 309: 1511-21.
Larance M., Lamond A.I. Multidimensional proteomics for cell biology. Nat Rev Mol Cell Biol. 2015; 16: 269-80.
MacArthur D.G., Balasubramanian S., Frankish A., Huang N., Morris J., Walter K. et al. A Systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012; 335: 823-8.
Mapstone M., Cheema A.K., Fiandaca M.S., Zhong X., Mhyre T.R., MacArthur L.H. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20: 415-8.
Mayers J.R., Wu C., Clish C.B., Kraft P. Torrence ME, Fiske BP, et al.Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014; 20: 1193-8.
Newgard C.B., An J., Bain J.R., Muehlbauer M.J., Stevens R.D., Lien L.F. et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009; 9: 311-26.
Nicholson J.K. Global systems biology, personalized medicine and molecular epidemiology. Mol Sys Biol. 2006; 2: 52.
Relling M.V., Evans W.E. Pharmacogenomic in the clinic. Nature. 2015; 526: 343-50.
Relling M.V., Gardner E.E., Sandborn W.J., Schmiegelow K., Pui C.H., Yee S.W. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013; 93: 324-5.
Rhee E.P., Cheng S., Larson M.G., Walford G.A., Lewis G.D., McCabe E. et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin. Invest. 2011; 121: 1402-11.
Richards AL, Merrill A.E., Coon J.J. Proteome sequencing goes deep. CurrOpin Chem Biol. 2015; 24: 11-7.
Riggs E.R., Jackson L., Miller D.T., Van Vooren S. Phenotypic information in genomic variant databases enhances clinical care and research: the International Standards for Cytogenomic Arrays Consortium experience. Hum Mutat. 2012; 33: 787-96.
Robinson P.N., Mungall C.J., Haendel M. Capturing phenotypes for precision medicine. Cold Spring Harb Mol Case Stud. 2015; 1: a000372. doi: 10.1101/ mcs.a000372.
Robinson P.N. Deep phenotyping for precision medicine. Hum Mutat. 2012; 33: 777-80.
Thakuria J.V., Zaranek A.W., Church G.M., Berry G.T. Back to the future: from genome to metabolome. Hum Mutat. 2012; 33: 809-12.
Topol E.J. Individualized medicine from prewomb to tomb. Cell. 2014; 157: 241-53.
Walther T.C., Mann M. Mass spectrometry-based proteomics in cell biology. J Cell Biol. 2010; 190: 491-500.
Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E. et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011; 17: 448-53.
Wang T.J., Ngo D., Psychogios N., Dejam A., Larson M.G., Vasan R.S. et al. 2-aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013; 123: 4309-17.
Wishart D.S., Jewison T., Guo A.C., Wilson M., Knox C., Liu Y. et al. HMDB 3.0 the human metabolome database in 2013. Nucleic Acids Res. 2013; 41: D801-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
